Skip to main content
Erschienen in: Virchows Archiv 6/2016

22.03.2016 | Original Article

Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development

verfasst von: Karin Malmberg, Charlotta Klynning, Angelique Flöter-Rådestad, Joseph W. Carlson

Erschienen in: Virchows Archiv | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Ovarian carcinoma is the deadliest gynecological malignancy. Previous studies have suggested that the fallopian tube may be the primary site for high-grade serous carcinoma. In prophylactic salpingo-oophorectomies from women with hereditary high risk for ovarian cancer, precursors can be assessed prior to onset and studied as a model for serous cancer precursor lesions. Epidemiologic studies indicate that carcinogenesis may be a result of chronic fallopian tube injury. The aims of this study were to (1) to examine the incidence of serous tubal intraepithelial carcinoma (STIC) in relation to other clinical parameters and (2) to evaluate whether chronic fallopian tube injury was related to cancer development. This study enrolled 101 women, comprising the following three groups: hereditary (n = 60), sporadic serous cancer (n = 18; endometrial cancers were excluded), and control (n = 23). The cases were histologically examined and clinical risk factors were collected. The histological changes were compared between different patients and correlated to clinical risk factors. STICs were identified primarily on the fallopian tube fimbria. The incidence of STIC was 3 % in the hereditary patients. In sporadic serous cancer cases, 61 % were associated with STIC and tubal carcinoma (p < 0.001). No differences in tubal injury or inflammation were seen when comparing the sporadic serous cancer group and the control group or within the hereditary group. STIC and invasive cancer were seen more often in the older patients than in the younger patients (p = 0.528). This small study, no correlation with chronic tubal injury or inflammation was identified.
Literatur
1.
Zurück zum Zitat Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol Off J Am Soc Clin Oncol 26:4160–4165. doi:10.1200/JCO.2008.16.4814 CrossRef Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol Off J Am Soc Clin Oncol 26:4160–4165. doi:10.​1200/​JCO.​2008.​16.​4814 CrossRef
2.
4.
Zurück zum Zitat Crum CP, McKeon FD, Xian W (2012) BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 22(Suppl 1):S29–34.CrossRefPubMed Crum CP, McKeon FD, Xian W (2012) BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 22(Suppl 1):S29–34.CrossRefPubMed
5.
Zurück zum Zitat De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15:23–34. doi:10.1016/s1470-2045(13)70546-1 CrossRefPubMed De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15:23–34. doi:10.​1016/​s1470-2045(13)70546-1 CrossRefPubMed
6.
7.
Zurück zum Zitat Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168–173. doi:10.1016/j.ygyno.2008.01.012 CrossRefPubMedPubMedCentral Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109:168–173. doi:10.​1016/​j.​ygyno.​2008.​01.​012 CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 27:1–9. doi:10.1097/pgp.0b013e31814b191f CrossRef Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP (2008) Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 27:1–9. doi:10.​1097/​pgp.​0b013e31814b191f​ CrossRef
10.
Zurück zum Zitat Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169. doi:10.1097/01.pas.0000213335.40358.47 CrossRefPubMed Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31:161–169. doi:10.​1097/​01.​pas.​0000213335.​40358.​47 CrossRefPubMed
12.
Zurück zum Zitat Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL (2011) ) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904CrossRefPubMed Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL (2011) ) Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 12:900–904CrossRefPubMed
13.
Zurück zum Zitat Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J (2010) DNA-repair pathway inhibitors for the treatment of ovarian cancer Cochrane Database Syst Rev:CD007929. doi:10.1002/14651858.CD007929.pub2 Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J (2010) DNA-repair pathway inhibitors for the treatment of ovarian cancer Cochrane Database Syst Rev:CD007929. doi:10.1002/14651858.CD007929.pub2
14.
Zurück zum Zitat Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236CrossRefPubMed Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30:230–236CrossRefPubMed
15.
Zurück zum Zitat Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP (2011) STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 3:625–634. Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, Crum CP (2011) STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 3:625–634.
17.
Zurück zum Zitat Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH (2010) Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstetrics Gynecol 115:945–952. doi:10.1097/AOG.0b013e3181da08d7 CrossRef Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Nogueras-Gonzalez GM, Schmeler KM, Gershenson DM, Lu KH (2010) Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstetrics Gynecol 115:945–952. doi:10.​1097/​AOG.​0b013e3181da08d7​ CrossRef
18.
Zurück zum Zitat Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467CrossRefPubMed Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91:1459–1467CrossRefPubMed
20.
Zurück zum Zitat Parazzini F, La Vecchia C, Negri E, Moroni S, Dal pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed Parazzini F, La Vecchia C, Negri E, Moroni S, Dal pino D, Fedele L (1996) Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 5:667–669PubMed
21.
Zurück zum Zitat Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456. doi:10.1002/path.1000 CrossRefPubMed Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195:451–456. doi:10.​1002/​path.​1000 CrossRefPubMed
22.
Zurück zum Zitat Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 4:447–451 Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology 4:447–451
23.
Zurück zum Zitat Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64CrossRefPubMed Salvador S, Gilks B, Köbel M, Huntsman D, Rosen B, Miller D (2009) The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer 19:58–64CrossRefPubMed
24.
Zurück zum Zitat Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 23:41–44. doi:10.1097/01.pgp.0000101080.35393.16 CrossRef Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 23:41–44. doi:10.​1097/​01.​pgp.​0000101080.​35393.​16 CrossRef
25.
Zurück zum Zitat Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 21:101–107CrossRef Seidman JD, Sherman ME, Bell KA, Katabuchi H, O’Leary TJ, Kurman RJ (2002) Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 21:101–107CrossRef
26.
Zurück zum Zitat Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H (2009) Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers modern pathology: an official journal of the United States and Canadian Academy Of Pathology. Inc 22:1133–1138. doi:10.1038/modpathol.2009.89 Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H (2009) Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers modern pathology: an official journal of the United States and Canadian Academy Of Pathology. Inc 22:1133–1138. doi:10.​1038/​modpathol.​2009.​89
27.
Zurück zum Zitat Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49:3670–3674PubMed
29.
Zurück zum Zitat Tone AA, Virtanen C, Shaw P, Brown TJ (2012) Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis Clinical cancer research. Off J Am Assoc Cancer Res 18:4334–4344. doi:10.1158/1078-0432.CCR-12-0199 CrossRef Tone AA, Virtanen C, Shaw P, Brown TJ (2012) Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis Clinical cancer research. Off J Am Assoc Cancer Res 18:4334–4344. doi:10.​1158/​1078-0432.​CCR-12-0199 CrossRef
Metadaten
Titel
Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development
verfasst von
Karin Malmberg
Charlotta Klynning
Angelique Flöter-Rådestad
Joseph W. Carlson
Publikationsdatum
22.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 6/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-1928-7

Weitere Artikel der Ausgabe 6/2016

Virchows Archiv 6/2016 Zur Ausgabe

Editorial

In this issue

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …